Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin

被引：4
|
作者：
Wang, Chen [1 ]
McGraw, Kathy L. [2 ]
McLemore, Amy F. [2 ]
Komrokji, Rami [2 ]
Basiorka, Ashley A. [2 ]
Al Ali, Najla [2 ]
Lancet, Jeffrey E. [2 ]
Padron, Eric [2 ]
Kosmider, Olivier [3 ]
Fontenay, Michaela [3 ]
Fenaux, Pierre [4 ]
List, Alan F. [2 ]
Sallman, David A. [2 ]
机构：
[1] Univ S Florida, Dept Internal Med, Morsani Coll Med, Tampa, FL USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[3] Ctr Univ Paris, Serv Hematol Biol, Hop Cochin, Assistance Publ Hop Paris, Paris, France
[4] Hop St Louis, Grp Francophone Myelodysplasies, Paris, France
来源：
HAEMATOLOGICA | 2022年 / 107卷 / 03期
关键词：
MECHANISM;
D O I：
10.3324/haematol.2021.278855
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：737 / 739
页数：3
相关论文
共 50 条
  • [31] Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels
    Santini, Valeria
    Almeida, Antonio
    Giagounidis, Aristoteles
    Skikne, Barry
    Beach, C. L.
    Weaver, Jerry
    Tu, Nora
    Fenaux, Pierre
    LEUKEMIA & LYMPHOMA, 2020, 61 (06) : 1475 - 1483
  • [32] Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
    List, A. F.
    Bennett, J. M.
    Sekeres, M. A.
    Skikne, B.
    Fu, T.
    Shammo, J. M.
    Nimer, S. D.
    Knight, R. D.
    Giagounidis, A.
    LEUKEMIA, 2014, 28 (05) : 1033 - 1040
  • [33] IMPACT OF GENE MUTATIONS ON RESPONSE TO LENALIDOMIDE AND OS IN LOWER-RISK NON-DEL(5Q) MDS PATIENTS INELIGIBLE/REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)
    Santini, V.
    Fenaux, P.
    Giagounidis, A.
    Platzbecker, U.
    Almeida, A.
    List, A. F.
    Zhong, J.
    Wu, C.
    Mavrommatis, K.
    Beach, C. L.
    MacBeth, K. J.
    LEUKEMIA RESEARCH, 2017, 55 : S14 - S14
  • [34] Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
    A F List
    J M Bennett
    M A Sekeres
    B Skikne
    T Fu
    J M Shammo
    S D Nimer
    R D Knight
    A Giagounidis
    Leukemia, 2014, 28 : 1033 - 1040
  • [35] Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
    Santini, Valeria
    Almeida, Antonio
    Giagounidis, Aristoteles
    Groepper, Stefanie
    Jonasova, Anna
    Vey, Norbert
    Mufti, Ghulam J.
    Buckstein, Rena
    Mittelman, Moshe
    Platzbecker, Uwe
    Shpilberg, Ofer
    Ram, Ron
    del Canizo, Consuelo
    Gattermann, Norbert
    Ozawa, Keiya
    Risueno, Alberto
    MacBeth, Kyle J.
    Zhong, Jianhua
    Seguy, Francis
    Hoenekopp, Albert
    Beach, C. L.
    Fenaux, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 2988 - +
  • [36] RESPONSE TO THALIDOMIDE AND CYCLOSPORINE IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROME WITHOUT ISOLATED DEL(5Q)
    Wang, J.
    Qin, T.
    Xu, Z.
    Zhang, Y.
    Gale, R.
    Fang, L.
    Zhang, H.
    Pan, L.
    Hu, N.
    Qu, S.
    Li, B.
    Xiao, Z.
    LEUKEMIA RESEARCH, 2015, 39 : S127 - S127
  • [37] IMPACT OF GENE MUTATIONS ON RESPONSE TO LENALIDOMIDE AND OS IN LOWER-RISK NON-DEL(5Q) MDS PATIENTS INELIGIBLE/REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)
    Santini, V.
    Fenaux, P.
    Giagounidis, A.
    Platzbecker, U.
    Almeida, A.
    List, A. F.
    Zhong, J.
    Wu, C.
    Mavrommatis, K.
    Beach, C. L.
    MacBeth, K. J.
    HAEMATOLOGICA, 2017, 102 : 39 - 39
  • [38] Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion
    Sanchez-Garcia, Joaquin
    del Canizo, Consuelo
    Lorenzo, Ignacio
    Nomdedeu, Benet
    Luno, Elisa
    de Paz, Raquel
    Xicoy, Blanca
    Valcarcel, David
    Brunet, Salut
    Marco-Betes, Victor
    Garcia-Pintos, Marta
    Osorio, Santiago
    Tormo, Mar
    Bailen, Alicia
    Cervero, Carlos
    Ramos, Fernando
    Diez-Campelo, Maria
    Such, Esperanza
    Arrizabalaga, Beatriz
    Azaceta, Gemma
    Bargay, Joan
    Arilla, Maria J.
    Falantes, Jose
    Serrano-Lopez, Josefina
    Sanz, Guillermo F.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (02) : 189 - 201
  • [39] Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial
    Komrokji, Rami S.
    Al Ali, Najla H.
    Padron, Eric
    Cogle, Christopher
    Tinsley, Sara
    Sallman, David
    Lancet, Jeffrey E.
    Lis, Alan F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (04): : 251 - 254
  • [40] Architectural and Functional Heterogeneity of Hematopoietic Stem/Progenitor Cells in Non-Del(5q) Myelodysplastic Syndromes
    Chesnais, Virginie
    Arcangeli, Marie-Laure
    Delette, Caroline
    Rousseau, Alice
    Diop, M'boyba Khadija
    Lefevre, Andrea
    Cheok, Meyling H.
    Chapuis, Nicolas
    Legros, Laurence
    Raynaud, Sophie
    Willems, Lise
    Bouscary, Didier
    Lauret, Evelyne
    Bernard, Olivier A.
    Kosmider, Olivier
    Pflumio, Francoise
    Fontenay, Michaela
    BLOOD, 2016, 128 (22)
12345